Bioblast Pharma Ltd., a clinical-stage biotechnology company, focuses on the development of clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. It develops Trehalose 90mg/mL IV solution, a protein stabilizer and autophagy enhancer to treat patients with oculopharyngeal muscular dystrophy and spinocerebellar ataxia type 3. The company was founded in 2012 and is headquartered in Tel Aviv, Israel.
http://www.priceseries.com/trade/ORPN-Bio-Blast-Pharma-Ltd-stock-gains-26-percent-a-Trade-Record-by-priceSeries-2018051620180518.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments